Didn't both RAP products fail to meet expectations in clinical trials?And have a higher share price before the covid product ever existed? It's been well pumped under varying circumstances over the years I think 21c is a great result.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%